(096) Evaluation of Fam-trastuzumab Deruxtecan Tolerability in Solid Tumor Patients

Poster Abstract:

Background: Fam-trastuzumab deruxtecan (T-DXd) is a human epidermal growth factor receptor 2 (HER2)-directed antibody drug conjugate indicated for previously treated HER2-positive or HER2-low unresectable or metastatic breast cancer, HER2-positive locally advanced or metastatic gastric cancer and HER2-mutant unresectable or metastatic non-small cell lung cancer. In the series of DESTINY studies, most common adverse events experienced with T-DXd treatment included nausea, vomiting, cytopenias, hepatotoxicity and respiratory infections with up to 16% of patients discontinuing treatment due to intolerance. Although rare, interstitial lung disease (ILD)/pneumonitis was reported in up to 13% of patients and warrants close monitoring as it has been associated with fatalities in up to 2.2% of patients.

Objective: This real-world study will evaluate the overall tolerability of T-DXd in all solid tumor patients and explore pre-disposing factors for those with documented intolerance or adverse events.

Methods: This is an institutional review board approved, single center, retrospective, observational cohort study of adult patients treated at our institution between December 1, 2019 to August 30, 2023 who received at least one dose of T-DXd for any indication.
 
The electronic medical record will be used to gather data including demographic and clinical information. The primary endpoint is to assess the incidence and severity of thrombocytopenia, neutropenia, febrile neutropenia, cardiotoxicity, lung toxicity, hepatotoxicity, and infection among patients with exposure to T-DXd. Secondary endpoints include the incidence of treatment adjustments of T-DXd, antiemetic medication escalation and additional health care utilization because of adverse events.

Results: not available

Discussion/conclusion: not available

References (must also be included in final poster): 1. Enhertu [package insert]. Basking Ridge, NJ: Daiichi Sankyo, Inc; 2022.
2. Modi S, Saura C, Yamashita T, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Engl J Med. 2020; 382:610-621. doi:10.1056.
3. Cortés J, Kim SB, Chung WP, et al. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. N Engl J Med. 2022; 386:1143-1154. doi:10.1056.
4. Modi S, Jacot W, Yamashita T, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med. 2022; 387:9-20. doi:10.1056.
5. Goto K, Sang-We S, Kubo T, et al. LBA55 Trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutant metastatic non-small cell lung cancer (NSCLC): Interim results from the phase 2 DESTINY-Lung02 trial. Ann Oncol. 2022; 33(7);1422. doi: 10.1016.
6. Shitara K, Bang YJ, Iwasa S, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. N Engl J Med. 2020; 382:2419-2430. doi:10.1056.